Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tamoxifen for breast cancer prevention: safety warning.

× No keyword cloud information.

12 in total

Review 1. Breast cancer in Canada.

Authors:
Journal: Can Fam Physician Date: 1999-08 Impact factor: 3.275

2. The economic burden of physical inactivity in Canada.

Authors: P T Katzmarzyk; N Gledhill; R J Shephard
Journal: CMAJ Date: 2000-11-28 Impact factor: 8.262

Review 3. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update).

Authors: I Olivotto; M Levine
Journal: CMAJ Date: 2001-10-02 Impact factor: 8.262

4. Raloxifene and breast cancer.

Authors: J Lorraine
Journal: CMAJ Date: 2001-10-02 Impact factor: 8.262

5. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update).

Authors: M Levine
Journal: CMAJ Date: 2001-01-23 Impact factor: 8.262

Review 6. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Authors: M H Gail; J P Costantino; J Bryant; R Croyle; L Freedman; K Helzlsouer; V Vogel
Journal: J Natl Cancer Inst Date: 1999-11-03 Impact factor: 13.506

7. Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Authors: M Levine
Journal: CMAJ Date: 2001-03-06 Impact factor: 8.262

Review 8. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Authors: M Levine; J M Moutquin; R Walton; J Feightner
Journal: CMAJ Date: 2001-06-12 Impact factor: 8.262

9. Patient reluctance toward tamoxifen use for breast cancer primary prevention.

Authors: E R Port; L L Montgomery; A S Heerdt; P I Borgen
Journal: Ann Surg Oncol Date: 2001-08 Impact factor: 5.344

10. Hormone replacement therapy in relation to breast cancer.

Authors: Chi-Ling Chen; Noel S Weiss; Polly Newcomb; William Barlow; Emily White
Journal: JAMA Date: 2002-02-13 Impact factor: 56.272

3 in total

1. Weighing the risks and benefits of tamoxifen.

Authors: Michelle Greiver
Journal: CMAJ Date: 2003-01-07 Impact factor: 8.262

2. Breast cancer prevention in women with a BRCA1 or BRCA2 mutation.

Authors: Kelly A Metcalfe; Steven A Narod
Journal: Open Med Date: 2007-12-18

3. Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.

Authors: Di Zhang; Bijay Singh; Jessica Moerland; Owen Mitchell; Lizbeth Lockwood; Sarah Carapellucci; Srinivas Sridhar; Karen T Liby
Journal: Sci Rep Date: 2021-01-13 Impact factor: 4.379

3 in total